TCF3 and acute lymphoblastic leukemia: TCF3-HLF ALL is associated with expression of stem cell and myeloid markers, alterations of PAX5 (deletions) and the Ras signaling pathway [7,51] and sensitivity to therapies inhibiting BCL2 and the pre-B cell receptor [52,53], immunologic therapies [54], and to Aurora A kinase inhibitors [55].